Clinical trials: Nonsmall Cell Lung Cancer Stage III
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab…
- Trial name
- PACIFIC-9 (NCT05221840)
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 202 sites in United States, Australia and 18 more
- Volunteers
- 1,051 people
- Sponsor
- AstraZeneca
Lung Cancer
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002550
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- 16 sites in United States, South Africa
- Volunteers
- 429 people
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8
- Trial name
- NCT05136846
- Testing
- Carboplatin, Durvalumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma
- Trial name
- NCT00334815
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 61 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
ARCH is a randomised, stratified, multicentre, phase III trial. Protocol treatment consists of cemiplimab, 350 mg i.v., every 3 weeks, for 4 cycles, followed by 700 mg i.v., every 6 weeks for 6 cycles or until relapse or…
- Trial name
- ARCH (NCT06931717)
- Testing
- Cemiplimab
- Where
- 35 sites in Austria, Estonia and 7 more
- Volunteers
- 390 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Non-small Cell Lung Cancer
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with.
- Trial name
- NCT07672223
- Testing
- SYS6010, Enlonstobart, Tislelizumab
- Volunteers
- 570 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer.
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06096844
- Testing
- Carboplatin, Computed Tomography, Magnetic Resonance Imaging
- Where
- 328 sites in United States
- Volunteers
- 304 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
This randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work compared to whole-brain radiation therapy and…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00096265
- Testing
- 3-Dimensional Conformal Radiation Therapy, Erlotinib Hydrochloride, Stereotactic Radiosurgery
- Where
- 83 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00217698
- Testing
- cisplatin, gefitinib, gemcitabine hydrochloride
- Where
- 14 sites in Switzerland
- Volunteers
- 63 people
- Sponsor
- Swiss Cancer Institute
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and…
- Conditions
- Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
- Trial name
- NCT07608159
- Testing
- Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy
- Volunteers
- 201 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Squamous Non-small Cell Lung Cancer
Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)
The study's hypothesis is that using Nivolumab as early switch maintenance, after 4-6 cycles of standard first-line chemotherapy, might improve survival in patients with advanced stage squamous NSCLC.
- Trial name
- EDEN (NCT03542461)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution, Best Supportive Care
- Where
- 31 sites in Italy
- Volunteers
- 125 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Non-small Cell Lung Cancer, Breast Cancer
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00327288
- Testing
- imexon, docetaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- AmpliMed Corporation
Non Small Cell Lung Cancer, Lung Cancer Stage III
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
Single arm, Phase II trial of concurrent Durvalumab (MEDI 4736) and radiotherapy followed by consolidative Durvalumb (MEDI 4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT04003246
- Testing
- Thoracic RT and Durvalumab, Consolidative Durvalumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center